Fig. 4From: The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidenceFrequency of treatment with high flow nasal cannula (HFNC) ventilation among preterms in the three RSV epidemic seasons (2014–2015, 2015–2016 and 2016–2017). a Whole preterm population. b The 29- < 33 wGA subgroup. c The 33- < 36 wGA subgroupBack to article page